Skye Bioscience
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
11250 El Camino Real Ste 100, San Diego,...Phone Number
(858) 410-0266Website
www.skyebioscience.comRevenue
-Stock Symbol
SKYEIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
1
1
1
About Skye Bioscience
Skye Bioscience, Inc. is a clinical-stage biotechnology company headquartered in San Diego, California, and publicly traded on Nasdaq under the ticker SKYE. The company develops next-generation therapies targeting G-protein-coupled receptors (GPCRs) for obesity, overweight, and related metabolic diseases. Its lead candidate, nimacimab, is a CB1 receptor antibody being evaluated in combination with GLP-1 therapies for weight loss in patients with obesity. Skye conducts research and development, manages clinical trials, and pursues strategic partnerships and licensing opportunities to advance its metabolic health pipeline.Explore more
Skye Bioscience Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Skye Bioscience your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Skye Bioscience had a recent Job posting/layoffs
Check if Skye Bioscience has recently received funding, and reach out quickly before it becomes old news!
Skye Bioscience, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Skye Bioscience recently announced quarterly report
Product Launch: Get notified when Skye Bioscience launches new products
Check out if Skye Bioscience is spiking on competitors!
Funding: Get notified immidiatlly once Skye Bioscience has new funding data
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Skye Bioscience
Recommended Actions
Reach out to Masked Content who joined Skye Bioscience as Masked Content
Find 2 more new buyers
Compare Similar Companies to Skye Bioscience
Compare insights from companies similar to Skye Bioscience, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Skye Bioscience is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Skye Bioscience is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Skye Bioscience.
Skye Bioscience financials insights
Gather financial insights about Skye Bioscience, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Stock Offering
$16.6M
2020
Share Placement
$7M
2024
Share Placement
$50.3M
Skye Bioscience Tech Stack
A closer look at the technologies used by Skye Bioscience
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Person-Based
Spending/Investment, Corporate Strategy
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Person-Based
Person-Based
Executive Moves
Skye Bioscience News & Media
Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings
Companies to hold a joint conference call on August 14, 2026 at 10 a.m. ETSkye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1
No Serious Adverse Events or Adverse Events of Special Interest Were Reported Following 4 Weeks of Treatment No Serious Adverse Events or Adverse Events of Special Interest Were Reported Following 4 Weeks of TreatmentUPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye” or the “Company”), a clinical stage biotechnology company developing next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related conditions, today reported financial results for the first quarter ended March 31, 2026, along with recent business updates and anticipated milestones.Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye” or the “Company”), a clinical stage biotechnology company developing next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related conditions, today reported financial results for the first quarter ended March 31, 2026, along with recent business updates and anticipated milestones. “Since our March update, execution has focused on turning CBeyond into a Phase 2
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Skye Bioscience
Sign Up For FreeTo access detailed company insights
Skye Bioscience, Inc. is a clinical-stage biotechnology company headquartered in San Diego, California, and publicly traded on Nasdaq under the ticker SKYE. The company develops next-generation therapies targeting G-protein-coupled receptors (GPCRs) for obesity, overweight, and related metabolic diseases. Its lead candidate, nimacimab, is a CB1 rec... Read More
